Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

GR1ZZLYBEARZ Oct. 31 at 7:56 AM

$AKBA $AKBA there’s too much lining up for this not to be a push down before a rip. So many potential catalysts in the next 1-6 months. Short volume decreased from the 60-70% area tues/wed to 48% yesterday… short days to cover went from 16 a few days ago down to 3 yesterday.

1 · Reply

LiquidThetaOptions Oct. 31 at 7:32 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AKBA Current Share Price: $2.10 Contracts: $AKBA January 15, 2027 $2 Calls Scale in: $0.80- $0.98 Scale out: $1.24-$1.60 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com

0 · Reply

SPECTRAL1 Oct. 31 at 7:07 AM

$AKBA

0 · Reply

BioLove Oct. 31 at 7:04 AM

$AKBA would like to see the price hold the low $2 s line until earnings...this is a very volatile sector/stock, and that would be a good sign. Of course, earnings will tell the story

0 · Reply

Azazel22 Oct. 31 at 5:44 AM

$AKBA this stock is a dud and i feel like i wasted to much time and money on it unfortunately

1 · Reply

MoneyGroupLLC Oct. 31 at 4:34 AM

Enter: $AKBA Calls Strike Price: $2 Expiry Date: NOV 21 2025 Buy in Price: $0.15 - $0.15 Sell Price: $0.31 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

piratepotatoman Oct. 31 at 3:31 AM

$AKBA 1.25 key entry

1 · Reply

Value_Runner Oct. 31 at 2:56 AM

$AKBA kid accounts at fidelity can’t buy stocks below $5. Come on butler, get this thing moving! My kids want to buy some shares!!! Get us out of “penny stock” land! https://www.fidelity.com/go/youth-account/overview

0 · Reply

rvc617423 Oct. 31 at 2:50 AM

$AKBA hear this absurd and totally irrational thought - lmao, alright imagine if this was purposely dropped to $2 so that butler goes and offers a buyback of 25 million shares @ the offering price 🤔🤨🧐 and on that note, time for bed 😆

1 · Reply

cashupfront Oct. 31 at 2:31 AM

$AKBA somebody needs to ban this guy for Over hyping this shit Tired of your posts Mr.pithetic

1 · Reply

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

Oct 29, 2025, 2:13 PM EDT - 1 day ago

FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug

Oct 28, 2025, 4:30 PM EDT - 2 days ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 10 days ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Oct 1, 2025, 4:05 PM EDT - 4 weeks ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 1:34 AM EDT - 2 months ago

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2025, 8:17 AM EDT - 2 months ago

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 21, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 7, 2025, 7:34 PM EDT - 3 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 3 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:00 AM EDT - 3 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 8, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 4, 2025, 8:00 AM EDT - 5 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 13, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:44 PM EDT - 6 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 6 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 8 months ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Mar 19, 2025, 10:17 PM EDT - 8 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 8 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 8 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 8 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 8 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Feb 10, 2025, 5:43 AM EST - 9 months ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Jan 13, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 11 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 11 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 1 year ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 1 year ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 1:59 PM EST - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 10, 2024, 8:00 AM EDT - 1 year ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Aug 10, 2024, 1:00 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

GR1ZZLYBEARZ Oct. 31 at 7:56 AM

1 · Reply

LiquidThetaOptions Oct. 31 at 7:32 AM

0 · Reply

SPECTRAL1 Oct. 31 at 7:07 AM

$AKBA

0 · Reply

BioLove Oct. 31 at 7:04 AM

$AKBA would like to see the price hold the low $2 s line until earnings...this is a very volatile sector/stock, and that would be a good sign. Of course, earnings will tell the story

0 · Reply

Azazel22 Oct. 31 at 5:44 AM

$AKBA this stock is a dud and i feel like i wasted to much time and money on it unfortunately

1 · Reply

MoneyGroupLLC Oct. 31 at 4:34 AM

0 · Reply

piratepotatoman Oct. 31 at 3:31 AM

$AKBA 1.25 key entry

1 · Reply

Value_Runner Oct. 31 at 2:56 AM

0 · Reply

rvc617423 Oct. 31 at 2:50 AM

1 · Reply

cashupfront Oct. 31 at 2:31 AM

$AKBA somebody needs to ban this guy for Over hyping this shit Tired of your posts Mr.pithetic

1 · Reply

Holy_boy Oct. 31 at 2:31 AM

$AKBA I predict the following scenario with the next gen HIF-PHI such as AB9030. Akebia will conduct phase 2/3 study on AB9030 on ARDS indication. If study result good, move AB9030 to phase 3 NDD CKD indication down the road. Phase 3 study on ARDS is much cheaper to carry out than CKD indication. The advantage of this pathway (compared to pursue Vada phase 3 NDD CKD study which is now cancelled) is longer patent protection, and getting ARDS indication/rev along the way, and higher chance of success with the most expensive study on NDD CKD indication. I see this pattern emerging in $ARDX latest ER where they talked about their next gen molecule in the pipeline. It is becoming easier for biopharma to modify their working molecules to improve its efficacy and safety profile, by harnessing new research tech like AI.

4 · Reply

Mr_Pithy Oct. 31 at 1:36 AM

$AKBA TODAY MARKS EIGHT MONTHS FROM JUNE 30, 2026. “I always said AKBA is a $30 stock just based on the Vafseo dialysis dependent indication.” (10-28-25); “Only price target now is $30 by June 2026.” (08-10-25); “So a $30 June 30, 2026 target price given my revenue model is totally fine and is in the lower end of the fair value range.”($24-$67) (08-08-25, 09:23 p.m.); “$30 mark by June 30, 2026 is my only prediction.” (08-08-25, 10:01 a.m.); “EOY $30 stock price gets extended out to June 30, 2026.” (08-08-25, 9:54 a.m.); Thank you @hsainu. Good luck 🍀

3 · Reply

BULLZ820 Oct. 31 at 12:34 AM

$AKBA hate to say it but unless the earnings is absolutely crazy good, even if it beats and is impressive but not like 200m, it will continue to be this way. Maybe down into 1s which is crazy for probably 300m+ in sales this year

8 · Reply

Justinkorr Oct. 31 at 12:24 AM

$AKBA The day after a 32% crash, the stock couldn’t even rebound by 0.1%. At this point, I think the company’s only real hope is a buyout, and I just hope V is an appealing enough drug for potential buyers. Honestly, if someone offered me $3.5 to $4 per share, I’d sell without hesitation.

2 · Reply

piratepotatoman Oct. 31 at 12:18 AM

$AKBA thinking about reentering but only around 1.25-1.5

3 · Reply

sundancehold Oct. 30 at 11:59 PM

$AKBA We've been 100% controlled by some short outfit for at least 8 months. I assume they're dark pooling shares over to tutes. Anyone that has any doubts, check the daily evidence in the level 2 bid/ask stack at 3:57-3:59 PM EST. every single day. Most scoff at Mo, but I'm 98% certain his crew is the outfit.

1 · Reply

viber7 Oct. 30 at 11:54 PM

$AKBA 20% of patients had GI side effects on V. So 250K patients = 60% of 0.8 X 550K TAM. When do you think we get that high number? Probably 2027-8. So your PPS target of 8 is valid 2-3 years from now for DD alone. Any earlier would require Davita and Fresenius to be completely committed to V by next summer 2026. Davita, OK. Fresenius not sure.

1 · Reply

thenewguy77 Oct. 30 at 11:52 PM

$AKBA So the math ain’t matching friends! As of yesterday and today the market cap is at around $550MM. Let’s assume for argument that for some reason V had zero growth and this quarter and aux holds its own as it has the past few quarters. That would mean V would be valued at 60MM (15mm per quarter) and aux would be valued at 200MM (50MM per quarter). Then we add the appropriate cash and cash equivalents at 140MM. The total value of the company would be at around 400MM. So somehow the market is value this company at nearly zero growth. I think once earnings come out, that will cause the reset we need to get us away from $2 a share. My estimates based on pure sales and a conservative multiple of 4x since this is a growth stock is 1.2BB. That’s 100MM of V, 200MM of aux and 140MM in cash.

2 · Reply

DonnyDonowitz Oct. 30 at 11:36 PM

$AKBA old legend here MaxbeakWettage's wife once said "WTF are you doing investing this much money in a CKD drug company!"

0 · Reply

Masonic11 Oct. 30 at 11:27 PM

$AKBA the grinch is a bitch.

1 · Reply

DollaDollaPils Oct. 30 at 11:19 PM

$AKBA

0 · Reply

Soheil444 Oct. 30 at 11:18 PM

$AKBA problem is no matter how good earnings is price will still drop. so regardless if bad er we drop if good er we drop . thats what sucks about this stock

1 · Reply

Market Cap	556.80M
Revenue (ttm)	160.18M
Net Income (ttm)	-69.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	115.88
Profit Margin	-43.33%
Debt to Equity Ratio	1.61

Volume	9,158,899
Avg Vol	3,826,596
Day's Range	N/A - N/A
Shares Out	265.15M
Stochastic %K	3%
Beta	0.68
Analysts	Strong Sell
Price Target	$6.40